Consensus Guidelines on Long-Acting Growth Hormone Treatment for Pediatric GH Deficiency

Overview

International experts have developed consensus guidelines for the use of long-acting growth hormone (LAGH) therapies in children with growth hormone deficiency. These guidelines address patient selection, dosing, administration, adherence, and highlight current knowledge gaps, emphasizing the potential benefits of LAGH over daily injections.

Background

Growth hormone deficiency in children has traditionally been treated with daily recombinant human GH injections, which often suffer from poor adherence impacting growth outcomes. Recently, several LAGH formulations have demonstrated noninferiority to daily GH in phase III trials and offer reduced injection frequency, potentially improving adherence and quality of life. Despite these advances, real-world long-term data on LAGH use in pediatric populations remain limited, necessitating expert consensus to guide clinical practice.

Data Highlights

Key Findings

• LAGH therapies reduce injection frequency compared to daily GH, potentially decreasing treatment burden and improving quality of life.
• Phase III pivotal trials show LAGH formulations are noninferior in efficacy and safety to daily GH injections in children with GH deficiency.
• Adherence to daily GH is often suboptimal, with studies showing missed doses correlate with reduced height velocity.
• Patients and caregivers generally prefer LAGH due to convenience and perceived better adherence.
• Current data on LAGH are mostly from clinical trials; long-term, real-world evidence is lacking.
• Consensus guidelines provide practical recommendations on patient selection, dosing adjustments, initiation, switching, and management of missed doses.

Clinical Implications

Clinicians should consider LAGH formulations as a viable alternative to daily GH injections for pediatric patients with GH deficiency, especially in cases where adherence is a concern. Patient and caregiver preferences for reduced injection frequency may enhance treatment compliance and outcomes. However, clinicians must remain vigilant due to limited long-term real-world data and continue to monitor treatment efficacy and safety closely.

Conclusion

LAGH therapies represent a promising advancement in pediatric GH deficiency treatment by potentially improving adherence and reducing treatment burden. Ongoing accumulation of long-term real-world data will be essential to refine these consensus guidelines and optimize patient care.

References

1. Maniatis et al. 2024 -- Consensus Guidelines on Long-Acting Growth Hormone Treatment for Pediatric Patients with Growth Hormone Deficiency